Evaluation of Quality of Life, Anxiety, and Depression in Patients with Primary Axillary Hyperhidrosis Undergoing Treatment with a Microwave Device: One-year Follow-up.
The study indicates that microwave treatment for primary axillary hyperhidrosis may lead to significant improvements in quality of life, anxiety, and depression, with 88.2% of patients achieving a notable reduction in sweating severity after one year.
Where it sits
this study against the rest of the ovagen (edl) corpusSummary and findings
This study evaluated the impact of microwave treatment on quality of life, anxiety, and depression in 103 patients with primary axillary hyperhidrosis. Patients received 1 or 2 treatments at 3-month intervals, with follow-up assessments conducted approximately 1 year after the first treatment. Statistically significant improvements were noted in the measured psychological parameters.
Abstract
Hyperhidrosis is associated with social and emotional stress, affecting quality of life. Microwave energy technology treats primary axillary hyperhidrosis by thermolysis of sweat glands. The successful reduction of sweating in patients with primary axillary hyperhidrosis after microwave treatment has been studied, but there is limited evidence on the psychological and long-term effects. This study examined patient- reported outcome measures including depression and anxiety in patients with primary axillary hyperhidrosis and the effect of microwave therapy on these parameters. Patients received 1 or 2 microwave-based treatments, within 3-month intervals. All patients were finally examined at approximately 1 year after the first treatment using the Hyperhidrosis Disease Severity Scale, Hyperhidrosis Quality of Life©, Dermatology Life Quality Index, and Hospital Anxiety and Depression Scale©. A total of 103 individuals with primary axillary hyperhidrosis were included in the study, with a Hyperhidrosis Disease Severity Scale score of 3 or 4. Statistically significant improvement in quality of life, anxiety, and depression scores were observed at 1-year follow-up. The primary endpoint, Hyperhidrosis Disease Severity Scale of 2 or less 1 year after the first treatment, was achieved by 88.2% of patients. No serious adverse side effects were observed.